So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease ...

Vertex Pharmaceuticals has seen its fair value estimate inch up from about $480 to roughly $485 per share as analysts refresh their models around a more constructive long term growth narrative.

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

US biopharma Vertex Pharmaceuticals today announced data from multiple studies demonstrating the clinical benefits of Casgevy ...

Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline. Vertex ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary ...